View profile

FarmaKology-Reuters Events : Pharma Predictions 2022-2027

Revue
 
 

FarmaKology

February 3 · Issue #95 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".


Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+14K Subscribers )!

Reuters Events : Pharma Predictions 2022-2027
Reuters Events : Pharma Predictions 2022-2027
After a staggering two years of unprecedented disruption and innovation, there’s no longer questions surrounding whether pharma can realize exceptional change. What’s less certain, however, is where and how pharma will direct its efforts to achieve ground-breaking transformation over the next five years.  
In Reuters Events’ exclusive new report, ‘Pharma Predictions 2022-2027’leaders across the industry have shared their predictions for pharma’s top priorities for the coming years, so you can see where our collective path may be headed. 
In addition to forecasts from our very own Reuters Events Pharma team, read predictions from leading experts including:  
Zhen Su, CEO, Marengo Therapeutics          
Oscar Segurado, Chief Medical Officer, ASC Therapeutics          
Eddie Power, VP, North America Medical Affairs, Pfizer  
Victoria DiBiaso, Global Head, Patient Informed Development & Health Value Translation, Sanofi        
Haider Alleg, Global Head of Digital, Ferring    
Mark Montgomery, Head, Business Insights & Execution, Commercial Acceleration, Novartis    
Keri Yale, Head, Patient Affairs & Engagement, Boehringer Ingelheim  
Trellis Usher, Founder & CEO, Nova Health Labs  
Reuters Events : Pharma Predictions 2022-2027
Reuters Events : Pharma Predictions 2022-2027
Farmakology
Farmakology
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue